Spykevax

We have tested 103 samples of healthcare workers from the Hospital Clínic in Barcelona, Spain (15 (link)), being 67% female and with a mean (SD) age of 40.6 (10.3) years old. Thirty-six were pre-exposed and unvaccinated; 20 were naïve and vaccinated with two doses of BNT162b2; 27 were vaccinated with one dose of mRNA-1273 (15 pre-exposed and 12 naïve), and 20 were naïve and vaccinated with 2 doses of mRNA-1273 (Supplementary Table 1). Previous exposure was defined as evidence of SARS-CoV-2 seropositivity or rRT-PCR positivity. Participants were recruited at the peak of the first wave of the pandemic in Barcelona, Spain, and followed up for one year. Venous or finger prick blood was collected at different visits after recruitment and immunization with one or two doses of the mRNA-1273 (Spykevax) (16 (link)) or two doses of the BNT162b2 (Comirnaty) (17 (link)), products from Moderna Biotech and Pfizer-BioNTech, respectively. Samples analyzed from the vaccinated participants were collected 10 to 21 days post 1^st dose and 10 to 34 days after the 2^nd dose. Samples analyzed from the pre-exposed non-vaccinated participants were collected 12 months after recruitment. Ten pre-pandemic samples were also assayed as negative controls. All plasma samples were isolated and cryopreserved at -80°C.